US Stock MarketDetailed Quotes

LSB LakeShore Biopharma

Watchlist

2.245
+0.085+3.94%

Trading Nov 4 12:20 ET

42.84MMarket Cap-394P/E (TTM)

LakeShore Biopharma Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual

YOY

Hide blank lines

(FY)Mar 31, 2024

(FY)Mar 31, 2023

(FY)Mar 31, 2022

(FY)Mar 31, 2021

Operating Cash Flow (Indirect Method)

Cash flow from continuing operating activities

-61.80%-295.23M

-5.14%-182.47M

29.63%-173.55M

-246.61M

Net income from continuing operations

-197.96%-433.46M

-37.24%-145.48M

44.74%-106M

---191.83M

Operating gains losses

-20,715.19%-4.45M

-107.80%-21.36K

1,001.39%273.98K

--24.88K

Depreciation and amortization

14.98%42.19M

17.76%36.69M

11.64%31.15M

--27.91M

Deferred tax

-2,016.94%-21.73M

-77.04%1.13M

-71.71%4.94M

--17.45M

Other non cash items

8.03%4.78M

16.79%4.42M

69.61%3.79M

--2.23M

Change In working capital

50.63%-45.79M

25.77%-92.75M

33.08%-124.94M

---186.68M

-Change in receivables

108.41%13.9M

-139.32%-165.25M

69.15%-69.05M

---223.82M

-Change in inventory

-375.23%-86.26M

79.71%-18.15M

-30.16%-89.46M

---68.73M

-Change in prepaid assets

-158.82%-5.29M

-84.82%8.99M

-59.64%59.23M

--146.77M

-Change in payables and accrued expense

-56.23%40.56M

536.95%92.66M

45.11%-21.21M

---38.63M

-Change in other current liabilities

-11.85%-5.09M

-19.86%-4.55M

-70.83%-3.8M

---2.22M

-Change in other working capital

44.06%-3.61M

-881.77%-6.45M

-1,382.67%-656.67K

---44.29K

Cash from discontinued investing activities

Operating cash flow

-61.80%-295.23M

-5.14%-182.47M

29.63%-173.55M

---246.61M

Investing cash flow

Cash flow from continuing investing activities

22.34%-44.25M

80.94%-56.98M

-186.77%-298.92M

-104.24M

Net PPE purchase and sale

16.02%-44.25M

82.16%-52.69M

-183.30%-295.31M

---104.24M

Net intangibles purchase and sale

--0

-18.63%-4.29M

---3.62M

--0

Cash from discontinued investing activities

Investing cash flow

22.34%-44.25M

80.94%-56.98M

-186.77%-298.92M

---104.24M

Financing cash flow

Cash flow from continuing financing activities

-35.34%205.26M

-12.92%317.45M

-50.69%364.56M

739.26M

Net issuance payments of debt

-178.25%-78.93M

-72.33%100.88M

4,315.43%364.56M

--8.26M

Net common stock issuance

--284.2M

--0

--1.59M

Net preferred stock issuance

----

--729.41M

Net other financing activities

----

--216.57M

----

Cash from discontinued financing activities

Financing cash flow

-35.34%205.26M

-12.92%317.45M

-50.69%364.56M

--739.26M

Net cash flow

Beginning cash position

36.63%370.37M

-30.58%271.07M

18,942.60%390.46M

--2.05M

Current changes in cash

-272.08%-134.22M

172.28%78M

-127.78%-107.91M

--388.41M

Effect of exchange rate changes

-51.18%10.4M

285.60%21.3M

-429,159.95%-11.48M

---2.67K

End cash Position

-33.43%246.55M

36.63%370.37M

-30.58%271.07M

--390.46M

Free cash flow

-41.73%-339.48M

49.31%-239.52M

-34.42%-472.48M

---351.49M

Currency Unit

CNY

Audit Opinions

Unqualified Opinion with Explanatory Notes

Unqualified Opinion

	(FY)Mar 31, 2024	(FY)Mar 31, 2023	(FY)Mar 31, 2022	(FY)Mar 31, 2021
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities	-61.80%-295.23M	-5.14%-182.47M	29.63%-173.55M	-246.61M
Net income from continuing operations	-197.96%-433.46M	-37.24%-145.48M	44.74%-106M	---191.83M
Operating gains losses	-20,715.19%-4.45M	-107.80%-21.36K	1,001.39%273.98K	--24.88K
Depreciation and amortization	14.98%42.19M	17.76%36.69M	11.64%31.15M	--27.91M
Deferred tax	-2,016.94%-21.73M	-77.04%1.13M	-71.71%4.94M	--17.45M
Other non cash items	8.03%4.78M	16.79%4.42M	69.61%3.79M	--2.23M
Change In working capital	50.63%-45.79M	25.77%-92.75M	33.08%-124.94M	---186.68M
-Change in receivables	108.41%13.9M	-139.32%-165.25M	69.15%-69.05M	---223.82M
-Change in inventory	-375.23%-86.26M	79.71%-18.15M	-30.16%-89.46M	---68.73M
-Change in prepaid assets	-158.82%-5.29M	-84.82%8.99M	-59.64%59.23M	--146.77M
-Change in payables and accrued expense	-56.23%40.56M	536.95%92.66M	45.11%-21.21M	---38.63M
-Change in other current liabilities	-11.85%-5.09M	-19.86%-4.55M	-70.83%-3.8M	---2.22M
-Change in other working capital	44.06%-3.61M	-881.77%-6.45M	-1,382.67%-656.67K	---44.29K
Cash from discontinued investing activities
Operating cash flow	-61.80%-295.23M	-5.14%-182.47M	29.63%-173.55M	---246.61M
Investing cash flow
Cash flow from continuing investing activities	22.34%-44.25M	80.94%-56.98M	-186.77%-298.92M	-104.24M
Net PPE purchase and sale	16.02%-44.25M	82.16%-52.69M	-183.30%-295.31M	---104.24M
Net intangibles purchase and sale	--0	-18.63%-4.29M	---3.62M	--0
Cash from discontinued investing activities
Investing cash flow	22.34%-44.25M	80.94%-56.98M	-186.77%-298.92M	---104.24M
Financing cash flow
Cash flow from continuing financing activities	-35.34%205.26M	-12.92%317.45M	-50.69%364.56M	739.26M
Net issuance payments of debt	-178.25%-78.93M	-72.33%100.88M	4,315.43%364.56M	--8.26M
Net common stock issuance	--284.2M	--0	--0	--1.59M
Net preferred stock issuance	----	----	----	--729.41M
Net other financing activities	----	--216.57M	----	----
Cash from discontinued financing activities
Financing cash flow	-35.34%205.26M	-12.92%317.45M	-50.69%364.56M	--739.26M
Net cash flow
Beginning cash position	36.63%370.37M	-30.58%271.07M	18,942.60%390.46M	--2.05M
Current changes in cash	-272.08%-134.22M	172.28%78M	-127.78%-107.91M	--388.41M
Effect of exchange rate changes	-51.18%10.4M	285.60%21.3M	-429,159.95%-11.48M	---2.67K
End cash Position	-33.43%246.55M	36.63%370.37M	-30.58%271.07M	--390.46M
Free cash flow	-41.73%-339.48M	49.31%-239.52M	-34.42%-472.48M	---351.49M
Currency Unit	CNY	CNY	CNY	CNY
Audit Opinions	Unqualified Opinion with Explanatory Notes	Unqualified Opinion	--	--

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data